Last reviewed · How we verify

Bentracimab (PB2452) Infusion — Competitive Intelligence Brief

Bentracimab (PB2452) Infusion (Bentracimab (PB2452) Infusion) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Heparin reversal agent; monoclonal antibody. Area: Hematology; Cardiovascular.

phase 3 Heparin reversal agent; monoclonal antibody Unfractionated heparin (UFH) Hematology; Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Bentracimab (PB2452) Infusion (Bentracimab (PB2452) Infusion) — SFJ Pharmaceuticals, Inc.. Bentracimab is a monoclonal antibody that binds to and neutralizes unfractionated heparin (UFH), rapidly reversing its anticoagulant effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bentracimab (PB2452) Infusion TARGET Bentracimab (PB2452) Infusion SFJ Pharmaceuticals, Inc. phase 3 Heparin reversal agent; monoclonal antibody Unfractionated heparin (UFH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Heparin reversal agent; monoclonal antibody class)

  1. SFJ Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bentracimab (PB2452) Infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/bentracimab-pb2452-infusion. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: